Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro.

Détails

ID Serval
serval:BIB_4046D503FB72
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro.
Périodique
Journal of neuroscience research
Auteur⸱e⸱s
Zurn A.D., Winkel L., Menoud A., Djabali K., Aebischer P.
ISSN
0360-4012 (Print)
ISSN-L
0360-4012
Statut éditorial
Publié
Date de publication
15/04/1996
Peer-reviewed
Oui
Volume
44
Numéro
2
Pages
133-141
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
We have previously shown that glial cell line-derived neurotrophic factor (GDNF), in addition to promoting the survival of dopaminergic neurons in cultures from embryonic rat ventral mesencephalon,also increases the activity of choline acetyltransferase (ChAT) in the cranial motoneurons present in these cultures (Zurn et al.: Neuroreport 6:113-118, 1994). By using the intermediate filament protein peripherin as a motoneuron marker, we report here that GDNF increases the number of motoneurons as well as the length of their neurites. Brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) also promote ChAT activity, motoneuron survival, and neurite outgrowth in these cultures, but to varying degrees. Although these three molecules have similar effects on cultured motoneurons, we provide evidence for a distinct mode of action of GDNF, BDNF, and CNTF, since combinations of GDNF and BDNF, GDNF and CNTF, and BDNF and CNTF have either additive or synergistic effects on ChAT activity and motoneuron number. In addition to the previously described motoneuron-specific neurotrophic factors BDNF and CNTF, GDNF combined with the latter two factors may provide an important tool for the treatment of human motoneuron diseases such as amyotrophic lateral sclerosis and spinal muscular atrophy, both by increasing efficiency of treatment, and by decreasing the likelihood of deleterious side-effects.
Mots-clé
Animals, Biomarkers, Brain-Derived Neurotrophic Factor, Cell Differentiation/drug effects, Cell Survival/drug effects, Cells, Cultured, Choline O-Acetyltransferase/metabolism, Ciliary Neurotrophic Factor, Drug Interactions, Embryo, Mammalian, Eye Proteins/analysis, Eye Proteins/biosynthesis, Glial Cell Line-Derived Neurotrophic Factor, Humans, Intermediate Filament Proteins/analysis, Intermediate Filament Proteins/biosynthesis, Membrane Glycoproteins, Mesencephalon/cytology, Motor Neuron Disease, Motor Neurons/drug effects, Motor Neurons/physiology, Nerve Growth Factors/pharmacology, Nerve Tissue Proteins/pharmacology, Neurites/drug effects, Neurites/physiology, Neurites/ultrastructure, Neuropeptides/analysis, Neuropeptides/biosynthesis, Peripherins, Phosphopyruvate Hydratase/analysis, Phosphopyruvate Hydratase/metabolism, Rats, Recombinant Proteins/pharmacology
Pubmed
Web of science
Création de la notice
28/01/2008 9:44
Dernière modification de la notice
09/04/2024 7:14
Données d'usage